This may be explained, in part, by lower expression of PD-L1 and TILs, with only 15% of HR+ breast cancer expressing PD-L1 CPS > 10.[30] There are no FDA-approved immunotherapies in HR + breast cancer to date. The gene discussed is CD274; the disease is breast cancer.